{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T06:30:46Z","timestamp":1792218646135,"version":"4.4.0"},"reference-count":96,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2026,2,8]],"date-time":"2026-02-08T00:00:00Z","timestamp":1770508800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Bispecific antibodies represent a pivotal advancement in treating relapsed\/refractory B-cell lymphomas, addressing unmet needs for patients with limited conventional options. This review examines CD20 \u00d7 CD3 bispecific antibodies (BsAbs) like mosunetuzumab, epcoritamab, odronextamab, and glofitamab, which link malignant B-cells and T-cells, thus inducing targeted tumor lysis. These IgG-like molecules activate T-cells, triggering proliferation and cytotoxic molecule release, bypassing MHC presentation. These agents have received regulatory approval for the treatment of various B-cell lymphomas and exhibit substantial efficacy, with high overall and complete response rates in diffuse large B-cell lymphoma and follicular lymphoma. However, their use is associated with immune-related toxicities. Cytokine Release Syndrome, which is a systemic inflammatory response due to a cytokine surge, and Immune Effector Cell-Associated Neurotoxicity Syndrome, linked to endothelial activation and blood\u2013brain barrier disruption, are critical concerns. This review details their mechanisms, grading, and management, including the use of tocilizumab and corticosteroids. Furthermore, BsAb therapy carries an elevated susceptibility to viral, bacterial, and opportunistic infections, often exacerbated by hypogammaglobulinemia. Expert recommendations for antimicrobial prophylaxis, including herpes and varicella zoster virus, pneumocystis, and immunoglobulin supplements are crucial for mitigating these risks. While BsAbs offer an \u201coff-the-shelf\u201d advantage, balancing their efficacy with comprehensive toxicity management is crucial for maximizing patient outcomes.<\/jats:p>","DOI":"10.3390\/medicina62020342","type":"journal-article","created":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T10:45:31Z","timestamp":1770633931000},"page":"342","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Bispecific Antibodies in B-Cell Lymphomas: Mechanisms, Efficacy, Toxicity, and Management"],"prefix":"10.3390","volume":"62","author":[{"given":"\u00c1d\u00e1m","family":"J\u00f3na","sequence":"first","affiliation":[{"name":"Department of Hematology, Faculty of Medicine, University of Debrecen, Member of ERN-EuroBloodNet (European Reference Network on Rare Haematological Diseases), H-4032 Debrecen, Hungary"},{"name":"Doctoral School of Clinical Medicine, University of Debrecen, H-4032 Debrecen, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-0225-3145","authenticated-orcid":false,"given":"D\u00e1vid","family":"T\u00f3thfalusi","sequence":"additional","affiliation":[{"name":"Department of Hematology, Faculty of Medicine, University of Debrecen, Member of ERN-EuroBloodNet (European Reference Network on Rare Haematological Diseases), H-4032 Debrecen, Hungary"},{"name":"Doctoral School of Clinical Medicine, University of Debrecen, H-4032 Debrecen, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1rp\u00e1d","family":"Ill\u00e9s","sequence":"additional","affiliation":[{"name":"Department of Hematology, Faculty of Medicine, University of Debrecen, Member of ERN-EuroBloodNet (European Reference Network on Rare Haematological Diseases), H-4032 Debrecen, Hungary"},{"name":"Doctoral School of Clinical Medicine, University of Debrecen, H-4032 Debrecen, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3507-9997","authenticated-orcid":false,"given":"Zs\u00f3fia","family":"Milt\u00e9nyi","sequence":"additional","affiliation":[{"name":"Department of Hematology, Faculty of Medicine, University of Debrecen, Member of ERN-EuroBloodNet (European Reference Network on Rare Haematological Diseases), H-4032 Debrecen, Hungary"},{"name":"Doctoral School of Clinical Medicine, University of Debrecen, H-4032 Debrecen, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,2,8]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1111\/bjh.70126","article-title":"Towards a Chemo-free Approach for Follicular Lymphoma","volume":"207","author":"Luminari","year":"2025","journal-title":"Br. J. Haematol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1016\/j.annonc.2024.08.2239","article-title":"Safety and Efficacy of Odronextamab in Patients with Relapsed or Refractory Follicular Lymphoma","volume":"35","author":"Kim","year":"2024","journal-title":"Ann. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"e593","DOI":"10.1016\/S2352-3026(24)00166-2","article-title":"Epcoritamab Monotherapy in Patients with Relapsed or Refractory Follicular Lymphoma (EPCORE NHL-1): A Phase 2 Cohort of a Single-Arm, Multicentre Study","volume":"11","author":"Linton","year":"2024","journal-title":"Lancet Haematol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/S1470-2045(22)00335-7","article-title":"Safety and Efficacy of Mosunetuzumab, a Bispecific Antibody, in Patients with Relapsed or Refractory Follicular Lymphoma: A Single-Arm, Multicentre, Phase 2 Study","volume":"23","author":"Budde","year":"2022","journal-title":"Lancet Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/s41408-024-00989-w","article-title":"Bi- and Tri-Specific Antibodies in Non-Hodgkin Lymphoma: Current Data and Perspectives","volume":"14","author":"Dalle","year":"2024","journal-title":"Blood Cancer J."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2321648","DOI":"10.1080\/2162402X.2024.2321648","article-title":"Trial Watch: Bispecific Antibodies for the Treatment of Relapsed or Refractory Large B-Cell Lymphoma","volume":"13","author":"Cassanello","year":"2024","journal-title":"OncoImmunology"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Gonz\u00e1lez-Barca, E. (2022). Role of Bispecific Antibodies in Relapsed\/Refractory Diffuse Large B-Cell Lymphoma in the CART Era. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.909008"},{"key":"ref_8","first-page":"1483","article-title":"New Bispecific Antibodies in Diffuse Large B-Cell Lymphoma","volume":"110","author":"Minson","year":"2025","journal-title":"Haematologica"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"6330","DOI":"10.3390\/curroncol30070467","article-title":"Toxicity Profile of Chimeric Antigen Receptor T-Cell and Bispecific Antibody Therapies in Multiple Myeloma: Pathogenesis, Prevention and Management","volume":"30","author":"Markouli","year":"2023","journal-title":"Curr. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1186\/s13045-015-0227-0","article-title":"Bispecific Antibodies and Their Applications","volume":"8","author":"Fan","year":"2015","journal-title":"J. Hematol. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Madsen, A.V., Pedersen, L.E., Kristensen, P., and Goletz, S. (2024). Design and Engineering of Bispecific Antibodies: Insights and Practical Considerations. Front. Bioeng. Biotechnol., 12.","DOI":"10.3389\/fbioe.2024.1352014"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/s40259-018-0299-9","article-title":"Expanding the Boundaries of Biotherapeutics with Bispecific Antibodies","volume":"32","author":"Husain","year":"2018","journal-title":"BioDrugs"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s40364-021-00294-9","article-title":"The Landscape of Bispecific T Cell Engager in Cancer Treatment","volume":"9","author":"Zhou","year":"2021","journal-title":"Biomark. Res."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Mohan, N., Ayinde, S., Peng, H., Dutta, S., Shen, Y., Falkowski, V.M., Biel, T., Ju, T., and Wu, W.J. (2024). Structural and Functional Characterization of IgG- and Non-IgG-Based T-Cell-Engaging Bispecific Antibodies. Front. Immunol., 15.","DOI":"10.3389\/fimmu.2024.1376096"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s40164-020-00189-9","article-title":"Recent Updates for Antibody Therapy for Acute Lymphoblastic Leukemia","volume":"9","author":"Li","year":"2020","journal-title":"Exp. Hematol. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Wang, Q., Chen, Y., Park, J., Liu, X., Hu, Y., Wang, T., McFarland, K.S., and Betenbaugh, M.J. (2019). Design and Production of Bispecific Antibodies. Antibodies, 8.","DOI":"10.3390\/antib8030043"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s13036-021-00272-7","article-title":"Structural Design of Tetravalent T-Cell Engaging Bispecific Antibodies: Improve Developability by Engineering Disulfide Bonds","volume":"15","author":"Lin","year":"2021","journal-title":"J. Biol. Eng."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1186\/s13045-017-0522-z","article-title":"Recent Advances of Bispecific Antibodies in Solid Tumors","volume":"10","author":"Yu","year":"2017","journal-title":"J. Hematol. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1038\/s42003-021-02565-5","article-title":"In Vivo Pharmacokinetic Enhancement of Monomeric Fc and Monovalent Bispecific Designs through Structural Guidance","volume":"4","author":"Shan","year":"2021","journal-title":"Commun. Biol."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Abdeldaim, D.T., and Schindowski, K. (2023). Fc-Engineered Therapeutic Antibodies: Recent Advances and Future Directions. Pharmaceutics, 15.","DOI":"10.3390\/pharmaceutics15102402"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"15521","DOI":"10.1038\/s41598-017-15748-0","article-title":"Rapid Purification of Human Bispecific Antibodies via Selective Modulation of Protein A Binding","volume":"7","author":"Zwolak","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"17253","DOI":"10.1038\/s41598-018-35489-y","article-title":"Engineering the Hinge Region of Human IgG1 Fc-Fused Bispecific Antibodies to Improve Fragmentation Resistance","volume":"8","author":"Suzuki","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_23","unstructured":"Madsen, A.V. (2023). Engineering Strategies for Design and Production of Bispecific Antibodies. [Ph.D. Thesis, Danmarks Tekniske Universite]."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1056\/NEJMoa2206913","article-title":"Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma","volume":"387","author":"Dickinson","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Kang, J., Sun, T., and Zhang, Y. (2022). Immunotherapeutic Progress and Application of Bispecific Antibody in Cancer. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.1020003"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/s41540-020-00145-7","article-title":"Mitigating the Risk of Cytokine Release Syndrome in a Phase I Trial of CD20\/CD3 Bispecific Antibody Mosunetuzumab in NHL: Impact of Translational System Modeling","volume":"6","author":"Hosseini","year":"2020","journal-title":"npj Syst. Biol. Appl."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Wei, J., Yang, Y., Wang, G., and Liu, M. (2022). Current Landscape and Future Directions of Bispecific Antibodies in Cancer Immunotherapy. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.1035276"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s40164-021-00250-1","article-title":"Recent Advances and Challenges of Bispecific Antibodies in Solid Tumors","volume":"10","author":"Wu","year":"2021","journal-title":"Exp. Hematol. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1007\/s00262-025-04036-w","article-title":"Immunological Synapse Formation as a Key Mechanism in T Cell-Dependent Bispecific Antibody-Mediated Immune Activation and Cytotoxicity","volume":"74","author":"Nakamura","year":"2025","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"102625","DOI":"10.1016\/j.ebiom.2019.102625","article-title":"DuoBody-CD3xCD20 Induces Potent T-Cell-Mediated Killing of Malignant B Cells in Preclinical Models and Provides Opportunities for Subcutaneous Dosing","volume":"52","author":"Engelberts","year":"2020","journal-title":"EBioMedicine"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"100810","DOI":"10.1016\/j.blre.2021.100810","article-title":"Bispecific Antibody Therapy, Its Use and Risks for Infection: Bridging the Knowledge Gap","volume":"49","author":"Longhitano","year":"2021","journal-title":"Blood Rev."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/s13045-019-0752-3","article-title":"Novel and Emerging Therapies for B Cell Lymphoma","volume":"12","author":"Ayyappan","year":"2019","journal-title":"J. Hematol. Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Salvaris, R., Ong, J., and Gregory, G.P. (2021). Bispecific Antibodies: A Review of Development, Clinical Efficacy and Toxicity in B-Cell Lymphomas. J. Pers. Med., 11.","DOI":"10.3390\/jpm11050355"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"14397","DOI":"10.1038\/s41598-021-93842-0","article-title":"Generation of T-Cell-Redirecting Bispecific Antibodies with Differentiated Profiles of Cytokine Release and Biodistribution by CD3 Affinity Tuning","volume":"11","author":"Haber","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1016\/S0140-6736(21)00889-8","article-title":"Dose Escalation of Subcutaneous Epcoritamab in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma: An Open-Label, Phase 1\/2 Study","volume":"398","author":"Hutchings","year":"2021","journal-title":"Lancet"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s13045-023-01462-0","article-title":"Mosunetuzumab and Lymphoma: Latest Updates from 2022 ASH Annual Meeting","volume":"16","author":"Cao","year":"2023","journal-title":"J. Hematol. Oncol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1182\/blood.2024025454","article-title":"Long-Term 3-Year Follow-up of Mosunetuzumab in Relapsed or Refractory Follicular Lymphoma after \u22652 Prior Therapies","volume":"145","author":"Sehn","year":"2024","journal-title":"Blood"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.clml.2023.12.005","article-title":"Mosunetuzumab Safety Profile in Patients with Relapsed\/Refractory B-Cell Non-Hodgkin Lymphoma: Clinical Management Experience from a Pivotal Phase I\/II Trial","volume":"24","author":"Matasar","year":"2023","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1007\/s40487-023-00245-4","article-title":"Multiple Real-World Data Sources in a Bayesian Framework to Inform Long-Term Survival Estimates of Mosunetuzumab in Patients with Follicular Lymphoma","volume":"11","author":"Alvarez","year":"2023","journal-title":"Oncol. Ther."},{"key":"ref_40","first-page":"2177","article-title":"Matching-Adjusted Indirect Comparison from the Lymphoma Epidemiology of Outcomes Consortium for Real World Evidence (LEO CReWE) Study to a Clinical Trial of Mosunetuzumab in Relapsed or Refractory Follicular Lymphoma","volume":"109","author":"Maurer","year":"2023","journal-title":"Haematologica"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"3754","DOI":"10.1182\/bloodadvances.2024015274","article-title":"Indirect Comparison of Epcoritamab vs. Chemoimmunotherapy, Mosunetuzumab, or Odronextamab in Follicular Lymphoma","volume":"9","author":"Danilov","year":"2025","journal-title":"Blood Adv."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1111\/bjh.70018","article-title":"Clinical Management of Bispecific Antibody Therapy for Lymphoma: A British Society for Haematology Good Practice Paper","volume":"207","author":"Chaganti","year":"2025","journal-title":"Br. J. Haematol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s13045-024-01594-x","article-title":"Comparisons of Treatment Outcomes of Epcoritamab versus Chemoimmunotherapy, Polatuzumab-Based Regimens, Tafasitamab-Based Regimens, or Chimeric Antigen Receptor T-Cell Therapy, in Third-Line or Later Relapsed\/Refractory Large B-Cell Lymphoma","volume":"17","author":"Rosenthal","year":"2024","journal-title":"J. Hematol. Oncol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"2653","DOI":"10.1038\/s41375-024-02410-8","article-title":"Epcoritamab in Relapsed\/Refractory Large B-Cell Lymphoma: 2-Year Follow-up from the Pivotal EPCORE NHL-1 Trial","volume":"38","author":"Karimi","year":"2024","journal-title":"Leukemia"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1007\/s10147-025-02788-0","article-title":"Efficacy and Safety of Epcoritamab in Japanese Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma: 3-Year Follow-up from the EPCORE NHL-3 Trial","volume":"30","author":"Izutsu","year":"2025","journal-title":"Int. J. Clin. Oncol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"906","DOI":"10.3324\/haematol.2023.283590","article-title":"The Changing Spectrum of Infection with BCMA and GPRC5D Targeting Bispecific Antibody (bsAb) Therapy in Patients with Relapsed Refractory Multiple Myeloma","volume":"109","author":"Hammons","year":"2023","journal-title":"Haematologica"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"e327","DOI":"10.1016\/S2352-3026(22)00072-2","article-title":"Odronextamab, a Human CD20\u00d7CD3 Bispecific Antibody in Patients with CD20-Positive B-Cell Malignancies (ELM-1): Results from the Relapsed or Refractory Non-Hodgkin Lymphoma Cohort in a Single-Arm, Multicentre, Phase 1 Trial","volume":"9","author":"Bannerji","year":"2022","journal-title":"Lancet Haematol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1182\/blood.2024027044","article-title":"Odronextamab Monotherapy in R\/R DLBCL after Progression with CAR T-Cell Therapy: Primary Analysis of the ELM-1 Study","volume":"145","author":"Topp","year":"2024","journal-title":"Blood"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1038\/s43018-025-00921-6","article-title":"Odronextamab Monotherapy in Patients with Relapsed\/Refractory Diffuse Large B Cell Lymphoma: Primary Efficacy and Safety Analysis in Phase 2 ELM-2 Trial","volume":"6","author":"Kim","year":"2025","journal-title":"Nat. Cancer"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/s13045-021-01113-2","article-title":"Evolving Therapeutic Landscape in Follicular Lymphoma: A Look at Emerging and Investigational Therapies","volume":"14","author":"Hanel","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Gonz\u00e1lez-Barca, E. (2023). Developing New Strategies for Relapsed\/Refractory Diffuse Large B-Cell Lymphoma. J. Clin. Med., 12.","DOI":"10.20944\/preprints202307.1943.v1"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1111\/bph.17458","article-title":"Novel Drugs Approved by the EMA, the FDA and the MHRA in 2024: A Year in Review","volume":"182","author":"Topouzis","year":"2025","journal-title":"Br. J. Pharmacol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"3821","DOI":"10.1007\/s00277-025-06438-3","article-title":"Efficacy and Safety of Glofitamab in Patients with R\/R DLBCL in Real Life Setting\u2014A Retrospective Study","volume":"104","author":"Gurion","year":"2025","journal-title":"Ann. Hematol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"3138","DOI":"10.3324\/haematol.2024.285255","article-title":"Sequencing of Cellular Therapy and Bispecific Antibodies for the Management of Diffuse Large B-Cell Lymphoma","volume":"109","author":"Melody","year":"2024","journal-title":"Haematologica"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s13045-023-01420-w","article-title":"Glofitamab Therapy for Diffuse Large B Cell Lymphoma: Latest Updates from the 2022 ASH Annual Meeting","volume":"16","author":"Wang","year":"2023","journal-title":"J. Hematol. Oncol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1002\/hon.3174","article-title":"Glofitamab in Relapsed\/Refractory Diffuse Large B-cell Lymphoma: Real-world Data","volume":"41","author":"Uzay","year":"2023","journal-title":"Hematol. Oncol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s40425-018-0343-9","article-title":"von Cytokine Release Syndrome","volume":"6","author":"Subklewe","year":"2018","journal-title":"J. Immunother. Cancer"},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Cosenza, M., Sacchi, S., and Pozzi, S. (2021). Cytokine Release Syndrome Associated with T-Cell-Based Therapies for Hematological Malignancies: Pathophysiology, Clinical Presentation, and Treatment. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22147652"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells","volume":"25","author":"Lee","year":"2018","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.emc.2018.04.001","article-title":"Rapid Fire: Infectious Disease Emergencies in Patients with Cancer","volume":"36","author":"Charshafian","year":"2018","journal-title":"Emerg. Med. Clin. North Am."},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Ayuketang, F.A., and J\u00e4ger, U. (2022). Management of Cytokine Release Syndrome (CRS) and HLH. The EBMT\/EHA CAR-T Cell Handbook, Springer.","DOI":"10.1007\/978-3-030-94353-0_26"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.annonc.2021.12.003","article-title":"Management of Adults and Children Receiving CAR T-Cell Therapy: 2021 Best Practice Recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA)","volume":"33","author":"Hayden","year":"2021","journal-title":"Ann. Oncol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"3978","DOI":"10.1200\/JCO.21.01992","article-title":"Management of Immune-Related Adverse Events in Patients Treated with Chimeric Antigen Receptor T-Cell Therapy: ASCO Guideline","volume":"39","author":"Santomasso","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Li, Y., Yue, M., Fu, R., Li, C., Wu, Y., Jiang, T., Li, Z., Ni, R., Li, L., and Su, H. (2022). The Pathogenesis, Diagnosis, Prevention, and Treatment of CAR-T Cell Therapy-Related Adverse Reactions. Front. Pharmacol., 13.","DOI":"10.3389\/fphar.2022.950923"},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Gust, J., Ponce, R., Liles, W.C., Garden, G.A., and Turtle, C.J. (2020). Cytokines in CAR T Cell\u2013Associated Neurotoxicity. Front. Immunol., 11.","DOI":"10.3389\/fimmu.2020.577027"},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Wen, L., Yu, J., Sun, Y., Song, Z., Liu, X., Han, X., Li, L., Qiu, L., Zhou, S., and Qian, Z. (2025). Adverse Events in the Nervous System Associated with Blinatumomab: A Real-World Study. BMC Med., 23.","DOI":"10.1186\/s12916-025-03913-6"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1186\/s13046-021-02148-6","article-title":"Mechanisms of Cytokine Release Syndrome and Neurotoxicity of CAR T-Cell Therapy and Associated Prevention and Management Strategies","volume":"40","author":"Xiao","year":"2021","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_68","doi-asserted-by":"crossref","unstructured":"Genoud, V., and Migliorini, D. (2023). Novel Pathophysiological Insights into CAR-T Cell Associated Neurotoxicity. Front. Neurol., 14.","DOI":"10.3389\/fneur.2023.1108297"},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"Yang, J., Ran, M., Li, H., Lin, Y., Ma, K., Yang, Y., Fu, X., and Yang, S. (2022). New Insight into Neurological Degeneration: Inflammatory Cytokines and Blood\u2013Brain Barrier. Front. Mol. Neurosci., 15.","DOI":"10.3389\/fnmol.2022.1013933"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1285898","DOI":"10.3389\/fmed.2023.1285898","article-title":"Endothelial Activation and Damage as a Common Pathological Substrate in Different Pathologies and Cell Therapy Complications","volume":"10","author":"Palomo","year":"2023","journal-title":"Front. Med."},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"Konsman, J.P. (2022). Cytokines in the Brain and Neuroinflammation: We Didn\u2019t Starve the Fire!. Pharmaceuticals, 15.","DOI":"10.3390\/ph15020140"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1172\/JCI129208","article-title":"State of the Art in CAR T Cell Therapy for CD19+ B Cell Malignancies","volume":"130","author":"Frigault","year":"2020","journal-title":"J. Clin. Investig."},{"key":"ref_73","doi-asserted-by":"crossref","unstructured":"Hellenthal, K.E.M., Brabenec, L., and Wagner, N. (2022). Regulation and Dysregulation of Endothelial Permeability during Systemic Inflammation. Cells, 11.","DOI":"10.3390\/cells11121935"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1172\/JCI25385","article-title":"Intensive Insulin Therapy Protects the Endothelium of Critically Ill Patients","volume":"115","author":"Langouche","year":"2005","journal-title":"J. Clin. Investig."},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"Rees, J. (2022). Management of Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS). The EBMT\/EHA CAR-T Cell Handbook, Springer.","DOI":"10.1007\/978-3-030-94353-0_27"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1007\/s12028-024-01995-3","article-title":"CAR-T Cell Therapy and the Neurointensivist","volume":"41","author":"Wijdicks","year":"2024","journal-title":"Neurocritical Care"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/s41577-021-00547-6","article-title":"Cytokine Release Syndrome and Associated Neurotoxicity in Cancer Immunotherapy","volume":"22","author":"Morris","year":"2021","journal-title":"Nat. Rev. Immunol."},{"key":"ref_78","first-page":"878","article-title":"Axicabtagene Ciloleucel: The First FDA-Approved CAR T-Cell Therapy for Relapsed\/Refractory Large B-Cell Lymphoma","volume":"10","author":"King","year":"2019","journal-title":"J. Adv. Pract. Oncol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s44228-022-00004-8","article-title":"The EBMT Immune Effector Cell Nursing Guidelines on CAR-T Therapy: A Framework for Patient Care and Managing Common Toxicities","volume":"4","author":"Ellard","year":"2022","journal-title":"Clin. Hematol. Int."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1007\/s00415-020-10237-3","article-title":"Neurological Updates: Neurological Complications of CAR-T Therapy","volume":"268","author":"Tallantyre","year":"2020","journal-title":"J. Neurol."},{"key":"ref_81","first-page":"21","article-title":"CAR T-Cell Therapy: Adverse Events and Management","volume":"10","author":"Adkins","year":"2019","journal-title":"J. Adv. Pract. Oncol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"e255","DOI":"10.1016\/S1470-2045(23)00159-6","article-title":"Prevention and Management of Adverse Events during Treatment with Bispecific Antibodies and CAR T Cells in Multiple Myeloma: A Consensus Report of the European Myeloma Network","volume":"24","author":"Ludwig","year":"2023","journal-title":"Lancet Oncol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/s41408-024-01091-x","article-title":"Improving Outcomes with Anti-BCMA Bispecific Antibodies with Attention to Infection","volume":"14","author":"Yee","year":"2024","journal-title":"Blood Cancer J."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s00277-017-3196-2","article-title":"Primary Prophylaxis of Invasive Fungal Infections in Patients with Haematological Malignancies: 2017 Update of the Recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society for Haematology and Medical Oncology (DGHO)","volume":"97","author":"Mellinghoff","year":"2017","journal-title":"Ann. Hematol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/s41408-024-00997-w","article-title":"Bispecific Antibodies and CAR-T Cells: Dueling Immunotherapies for Large B-Cell Lymphomas","volume":"14","author":"Trabolsi","year":"2024","journal-title":"Blood Cancer J."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"101598","DOI":"10.1016\/j.beha.2025.101598","article-title":"von Bispecific Antibody Therapy for Lymphoma","volume":"37","author":"Gerhard","year":"2024","journal-title":"Best Pract. Res. Clin. Haematol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/s13045-023-01482-w","article-title":"Bi- and Trispecific Immune Cell Engagers for Immunotherapy of Hematological Malignancies","volume":"16","author":"Sanz","year":"2023","journal-title":"J. Hematol. Oncol."},{"key":"ref_88","doi-asserted-by":"crossref","unstructured":"He, Y., Qiu, L., Chen, D., Ren, S.-H., Xiong, Y., Li, M., Dou, B.-T., Li, Y., Cen, Y., and Li, Y. (2025). CAR T-Cells vs. Bispecific Antibodies as Third- or Later-Line Treatment for Relapsed\/Refractory Follicular Lymphoma: A Literature Review and Meta-Analysis. Front. Immunol., 16.","DOI":"10.3389\/fimmu.2025.1611984"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"e433516","DOI":"10.1200\/EDBK_433516","article-title":"Bispecific Antibody Use in Patients with Lymphoma and Multiple Myeloma","volume":"44","author":"Braun","year":"2024","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1007\/s40487-025-00389-5","article-title":"Patient and Physician Perspectives on Multiple Myeloma Data Presented at ASCO and EHA 2025: A Podcast","volume":"13","author":"Ahlstrom","year":"2025","journal-title":"Oncol. Ther."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1158\/1078-0432.CCR-24-2247","article-title":"Clinical Pharmacology of Cytokine Release Syndrome with T-Cell\u2013Engaging Bispecific Antibodies: Current Insights and Drug Development Strategies","volume":"31","author":"Radtke","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"ref_92","doi-asserted-by":"crossref","unstructured":"Guo, X., Wu, Y., Ying, X., Xie, N., and Shen, G. (2023). Revolutionizing Cancer Immunotherapy: Unleashing the Potential of Bispecific Antibodies for Targeted Treatment. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1291836"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/j.clml.2025.04.002","article-title":"Feasibility and Safety of Outpatient Model for Administration of Bispecific Antibodies: Proceedings from an International Myeloma Society 21st Annual Meeting Oral Abstract","volume":"25","author":"Scott","year":"2025","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_94","first-page":"SP550","article-title":"Whither CAR T? Will the FDA Being Under the Hood and the Availability of Bispecifics Make These Therapies Less Attractive?","volume":"30","author":"Chao","year":"2024","journal-title":"Am. J. Manag. Care"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"3232","DOI":"10.1007\/s12325-024-02917-7","article-title":"Medicare Utilization and Cost Trends for CAR T Cell Therapies Across Settings of Care in the Treatment of Diffuse Large B-Cell Lymphoma","volume":"41","author":"Wu","year":"2024","journal-title":"Adv. Ther."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1080\/14796694.2024.2354157","article-title":"Practice Efficiency and Total Cost of Care with Bispecifics and CAR-T in Relapsed\/Refractory Diffuse Large B-Cell Lymphoma: An Institutional Perspective","volume":"20","author":"Lei","year":"2024","journal-title":"Future Oncol."}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/62\/2\/342\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T05:14:58Z","timestamp":1770959698000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/62\/2\/342"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,8]]},"references-count":96,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,2]]}},"alternative-id":["medicina62020342"],"URL":"https:\/\/doi.org\/10.3390\/medicina62020342","relation":{},"ISSN":["1648-9144"],"issn-type":[{"value":"1648-9144","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,8]]}}}